Skip to content
  • Investors
  • News & Events
  • Contact Us
Rigel Pharmaceuticals
  • Who We Are
  • Pipeline
  • Products
  • Join Our Team
  • Investors
  • News
  • Contact Us
Rigel Pharmaceuticals
  • Who We Are
  • Pipeline
  • Products
  • Join The Team
  • Investors
  • News
  • Contact Us
Investors

Investors

  • Overview
  • News & Events
    • Press Releases
    • Events & Presentations
    • Email Alerts
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • FAQ
  • Stock Data
    • Stock Quote
    • Charting
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Analyst Coverage
  • Governance
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents

Press Releases

  • News & Events

  • Press Releases
  • Events & Presentations
  • Email Alerts

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2017 Financial Results

Feb 27, 2018 7:30am EST

Rigel Pharmaceuticals, Inc. Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)

Feb 16, 2018 5:15pm EST

Rigel Pharmaceuticals, Inc. Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)

Jan 26, 2018 4:05pm EST

Rigel Pharmaceuticals, Inc. Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)

Jan 05, 2018 4:05pm EST

Rigel to Provide Business Review and Updated Phase 2 Results for Fostamatinib in AIHA at the 36th Annual J.P. Morgan Healthcare Conference

Jan 04, 2018 7:30am EST

Rigel Announces Departure of Chief Financial Officer

Dec 15, 2017 7:30am EST

Rigel Pharmaceuticals, Inc. Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)

Dec 08, 2017 7:05pm EST

Rigel to Present One-Year Efficacy and Safety Results for Fostamatinib in ITP at the 2017 American Society of Hematology Annual Meeting

Dec 08, 2017 7:30am EST

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Nov 17, 2017 4:05pm EST

Rigel Announces Third Quarter 2017 Financial Results and Provides Company Update

Nov 07, 2017 4:01pm EST
RSS
  • Prev
    • 1...
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    • ...31
    Next
    • Email Alerts
    • Tear Sheet
    • RSS News Feed
    • Terms of Use
    • Privacy Policy

    © 2021 Rigel Pharmaceuticals, Inc. All rights reserved.
    TAVALISSE and the Rigel arc logo are trademarks of Rigel Pharmaceuticals, Inc.
    TAVA_ITP-19277

    • facebook
    • twitter
    • linkedin
    © 2021 Rigel Pharmaceuticals • Powered by GeneratePress